News Sentiment

NTLA sentiment intelligence

Intellia Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.67 Week of 19 Jun 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+29.4% over one week, +24.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

StockWatch: Positive Phase III Data Sells Investors on Intellia

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 29.4% Price confirming higher
Trend fit Trend active 24.4% over four weeks
Fair value -18.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 25
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
simplywall.st 7
Stock Titan 6
Intellia Therapeutics 5
Simply Wall Street 4
TradingView 3
The Globe and Mail 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 20
Analyst action 4
Regulatory and legal 3
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Genetic Engineering and Biotechnology News Direct company coverage

StockWatch: Positive Phase III Data Sells Investors on Intellia

Intellia Therapeutics' shares surged after positive Phase III data for its gene-editing candidate, lonvoguran ziclumeran (lonvo-z), in hereditary angioedema (HAE). The therapy met primary and secondary endpoints, leading analysts to anticipate FDA approval and strong market adopt

Tone
Positive 74/100
Event
Regulatory and legal
Published
22 Jun 2026 00:40
Source
Genetic Engineering and Biotechnology News
Simply Wall Street Direct company coverage

Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing

Intellia Therapeutics (NTLA) shares surged 29.4% following positive Phase 3 HAELO trial data for its CRISPR therapy, lonvo-z, targeting hereditary angioedema. The company also filed a rolling biologics license application with the FDA and published results in the New England Jour

Tone
Positive 81/100
Event
Earnings
Published
21 Jun 2026 20:39
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data

Intellia Therapeutics (NTLA) is drawing attention after releasing positive Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema and submitting a rolling biologics license application to the FDA. Despite a recent 70.14% year-to-date share price in

Tone
Positive 65/100
Event
Market update
Published
19 Jun 2026 23:09
Source
Simply Wall Street
GuruFocus Direct company coverage

Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price

Intellia Therapeutics (NTLA) saw a significant stock price surge of 10.7% on June 17, 2026, driven by increased investor confidence in its CRISPR/Cas9 gene-editing technology. Despite a solid GF Score™ of 72, indicating strong growth prospects, the company's low profitability ran

Tone
Positive 77/100
Event
Market update
Published
17 Jun 2026 20:09
Source
GuruFocus
StocksToTrade Direct company coverage

NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads

Intellia Therapeutics Inc. (NTLA) stock surged by 10.24% following promising Phase 3 CRISPR gene-editing trial results for its drug lonvo-z, aimed at hereditary angioedema. The data, published in the New England Journal of Medicine and presented at EAACI 2026, showed significant

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:42
Source
StocksToTrade
BioSpace Direct company coverage

Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema

Intellia Therapeutics' CRISPR-based gene editing therapy, lonvo-z, showed significant efficacy in a Phase 3 study for hereditary angioedema, reducing disease attack episodes by 89% and moderate/severe attacks by 91%. Analysts predict lonvo-z could challenge Ionis Pharmaceuticals'

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 22:40
Source
BioSpace
TradingView Direct company coverage

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia Therapeutics (NTLA) shares surged 23.2% after announcing additional positive data from its phase III HAELO study for lonvo-z, an HAE gene-editing therapy. The latest data showed lonvo-z significantly reduced the monthly rates of HAE attacks, further demonstrating its pot

Tone
Positive 82/100
Event
Macro sensitivity
Published
16 Jun 2026 14:39
Source
TradingView
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

This article highlights recent analyst ratings for several healthcare companies. Wells Fargo maintained a Hold rating on Incyte (INCY), while TD Cowen and William Blair reiterated Buy ratings for Intellia Therapeutics (NTLA). Wells Fargo also maintained a Hold rating on Halozyme

Tone
Positive 71/100
Event
Analyst action
Published
16 Jun 2026 10:39
Source
The Globe and Mail
Market source Direct company coverage

Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results

Intellia Therapeutics saw its share price jump 23% following positive Phase 3 results for its hereditary angioedema (HAE) treatment, Lonvo-Z. The drug achieved an 87% reduction in monthly attacks compared to placebo and demonstrated favorable safety, with 62% of patients being at

Tone
Positive 93/100
Event
Earnings
Published
16 Jun 2026 03:10
Source
Market source
Investing.com Nigeria Direct company coverage

Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com

Intellia Therapeutics Inc.'s options trading volume significantly increased to 7,041 contracts on Monday morning, with call options representing the majority of the activity. The June 18, 2026 $13 and $14 call options saw substantial contract volumes. Shares of Intellia Therapeut

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jun 2026 16:09
Source
Investing.com Nigeria
Benzinga Direct company coverage

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics' gene-editing therapy, lonvo-z (previously NTLA-2002), has shown promising results in its Phase 3 HAELO trial for hereditary angioedema (HAE), demonstrating an 87% reduction in monthly HAE attacks compared to placebo. The data, presented at EAACI 2026 and pu

Tone
Positive 92/100
Event
Earnings
Published
15 Jun 2026 14:09
Source
Benzinga
Fierce Biotech Direct company coverage

Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment

Intellia Therapeutics has released additional positive phase 3 data for its one-time gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The results showed significant reductions in HAE attacks and improvements in quality of life, meeting secon

Tone
Positive 72/100
Event
Earnings
Published
15 Jun 2026 10:37
Source
Fierce Biotech
Stocktwits Direct company coverage

Why Is NTLA Stock Jumping 5% Premarket Today?

Intellia Therapeutics (NTLA) stock surged 5% premarket after releasing additional Phase 3 data for its CRISPR-based hereditary angioedema (HAE) treatment, Lonvo-z. The data showed an 89% reduction in attacks requiring rescue medication and significant quality-of-life improvements

Tone
Positive 92/100
Event
Market update
Published
15 Jun 2026 08:14
Source
Stocktwits
Simply Wall Street Direct company coverage

Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization

Intellia Therapeutics (NTLA) recently reported positive Phase 3 results for its gene-editing therapy, lonvo-z, for hereditary angioedema and has initiated a rolling biologics license application with the FDA. Despite this significant progress towards potential commercialization,

Tone
Neutral 50/100
Event
Earnings
Published
14 Jun 2026 12:39
Source
Simply Wall Street
Intellia Therapeutics Direct company coverage

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics announced additional positive Phase 3 results for lonvoguran ziclumeran (lonvo-z), its CRISPR-based investigational treatment for hereditary angioedema (HAE). The data from the HAELO clinical trial, presented at EAACI 2026 and published in The New England Jo

Tone
Positive 94/100
Event
Regulatory and legal
Published
13 Jun 2026 12:09
Source
Intellia Therapeutics
Stock Titan Direct company coverage

One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial

Intellia Therapeutics reported additional positive Phase 3 HAELO data for its CRISPR gene-editing treatment, lonvo-z, showing an 87% reduction in mean monthly hereditary angioedema (HAE) attacks compared to placebo. The trial also demonstrated a significant improvement in quality

Tone
Positive 74/100
Event
Market update
Published
13 Jun 2026 11:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Exploring High Growth Tech Stocks In The US Market

This article identifies and discusses high-growth tech stocks in the US market, noting the market's recent decline but overall annual growth. It highlights key companies like LightPath Technologies, Intellia Therapeutics, and AppLovin, detailing their financial performance, growt

Tone
Positive 71/100
Event
Market update
Published
11 Jun 2026 11:12
Source
Simply Wall Street
Stock Titan Direct company coverage

Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options

Intellia Therapeutics (NTLA) director Muna Bhanji was granted 9,200 Restricted Stock Units (RSUs) and 13,300 stock options, as detailed in a recent Form 4 filing. The RSUs increase her direct common stock holdings to 36,403 shares, while the stock options have an exercise price o

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 07:39
Source
Stock Titan
Stock Titan Direct company coverage

Intellia (NTLA) director Georgia Keresty receives stock awards and options grant

Intellia Therapeutics director Georgia Keresty received equity compensation, including 9,200 restricted stock units (RSUs) and stock options for 13,300 shares at an exercise price of $12.89 per share. Following these grants, her direct holdings in common stock increased to 41,083

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Intellia (NTLA) director receives 9,200 RSUs and 13,300 options

Intellia Therapeutics director Frank Verwiel was granted 9,200 restricted stock units (RSUs) and a stock option for 13,300 shares, reflecting new equity awards rather than open-market transactions. Following these grants, Verwiel directly holds 35,148 common shares and the new st

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options

Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Intellia (NTLA) director awarded RSUs and stock options in new grant

Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or t

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:10
Source
Stock Titan